From Wikipedia, the free encyclopedia
Jump to: navigation, search
Astex Therapeutics
Industry Pharmaceutical
Founded 1999
Headquarters Cambridge, England
Key people
Harren Jhoti (CEO)
Martin Buckland (CBO)
Products oncology treatments
Revenue not available

Astex Therapeutics was a biotechnology company focused on the discovery and development of drugs in oncology and other areas. Astex was founded in 1999 by Sir Tom Blundell,[1][2] Chris Abell & Harren Jhoti,[3] and is located in Cambridge, England.[4][5][6][7][8]

The company's research efforts focus on utilization of a proprietary "drug discovery engine" dubbed Pyramid. Astex has also solved the structure of two key cytochrome P450 isoenzymes involved in drug metabolism, 2C9 & 3A4, which the company hopes will help in optimizing the pharmacokinetic properties and safety of their lead compounds.

Astex Therapeutic's first drug candidate, a cell cycle inhibitor, entered Phase I clinical trials in 2005. Since that time they have created eight drugs that have progressed into the clinical stage of development.

Recent news[edit]

In September 2013, Astex was acquired by Otsuka Pharmaceutical for around $900 million.[9]

See also[edit]


  1. ^ Tom Blundell: Director on OpenCorporates
  2. ^ Congreve, M; Murray, C. W.; Blundell, T. L. (2005). "Structural biology and drug discovery". Drug Discovery Today 10 (13): 895–907. doi:10.1016/S1359-6446(05)03484-7. PMID 15993809. 
  3. ^ Williams, P. A.; Cosme, J; Vinkovic, D. M.; Ward, A; Angove, H. C.; Day, P. J.; Vonrhein, C; Tickle, I. J.; Jhoti, H (2004). "Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone". Science 305 (5684): 683–6. doi:10.1126/science.1099736. PMID 15256616. 
  4. ^ Repasky, M. P.; Murphy, R. B.; Banks, J. L.; Greenwood, J. R.; Tubert-Brohman, I; Bhat, S; Friesner, R. A. (2012). "Docking performance of the glide program as evaluated on the Astex and DUD datasets: A complete set of glide SP results and selected results for a new scoring function integrating Water Map and glide". Journal of Computer-Aided Molecular Design 26 (6): 787–99. doi:10.1007/s10822-012-9575-9. PMID 22576241. 
  5. ^ Novikov, F. N.; Stroylov, V. S.; Zeifman, A. A.; Stroganov, O. V.; Kulkov, V; Chilov, G. G. (2012). "Lead Finder docking and virtual screening evaluation with Astex and DUD test sets". Journal of Computer-Aided Molecular Design 26 (6): 725–35. doi:10.1007/s10822-012-9549-y. PMID 22569592. 
  6. ^ Wolfson, W (2006). "Fragmentary solutions. Astex therapeutics puts the pieces together". Chemistry & Biology 13 (8): 799–801. doi:10.1016/j.chembiol.2006.08.003. PMID 16931326. 
  7. ^ Mountain, V (2003). "Astex, Structural Genomix, and Syrrx. I can see clearly now: Structural biology and drug discovery". Chemistry & biology 10 (2): 95–8. PMID 12618177. 
  8. ^ Carr, R. A.; Congreve, M; Murray, C. W.; Rees, D. C. (2005). "Fragment-based lead discovery: Leads by design". Drug Discovery Today 10 (14): 987–92. doi:10.1016/S1359-6446(05)03511-7. PMID 16023057. 
  9. ^ Tim Kelly (5 September 2013). "Japan's Otsuka to buy cancer drug maker Astex Pharma". Reuters. 

Further reading[edit]